Nanoscope Therapeutics Press Releases
-
Nanoscope Therapeutics Announces First Patient Dosed in Phase 2b Clinical Trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa
July 19, 2021 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa
June 23, 2021 by Nanoscope Therapeutics
-
Nanoscope’s Optogenetic Gene Therapy Restores Clinically Meaningful Vision in 11 Patients Blinded by Retinitis Pigmentosa
June 3, 2021 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Announces New Clinical Advisory Board Appointments
April 19, 2021 by Nanoscope Therapeutics
-
Nanoscope’s Optical Gene Therapies to be Featured at Optogenetics and Optical Manipulation 2021 Conference
March 5, 2021 by Nanoscope Therapeutics
-
Nanoscope President to Deliver Talk on Gene Therapy for Retinal Diseases at Association for Ocular Pharmacology and Therapeutics Conference
March 3, 2021 by Nanoscope Therapeutics
-
Nanoscope® team conferred Phase II Retinal Organoid Challenge (ROC) award by National Institute of Health
February 2, 2021 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Receives Orphan Drug Designation for Gene Therapy of Blindness
January 25, 2021 by Nanoscope Therapeutics
-
Nanoscope Announces Presentation at the 2020 Annual Meeting of American Academy of Ophthalmology
November 13, 2020 by Nanoscope Therapeutics
-
Nanoscope received NIH support for its first-in-class delivery approach to restore vision
May 28, 2020 by Nanoscope Therapeutics
-
Nanoscope Receives NIH grants to recruit talent and advance optogenetic delivery platforms
January 25, 2020 by Nanoscope Therapeutics
